[Identification and validation of clinically relevant molecular alterations in prostate cancer]
Standard
[Identification and validation of clinically relevant molecular alterations in prostate cancer]. / Schlomm, T; Sültmann, H; Köllermann, Jens.
in: PATHOLOGE, Jahrgang 30, Nr. 2, 2, 2009, S. 111-116.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Identification and validation of clinically relevant molecular alterations in prostate cancer]
AU - Schlomm, T
AU - Sültmann, H
AU - Köllermann, Jens
PY - 2009
Y1 - 2009
N2 - Significant cellular alterations required for the development and progression of cancers are detectable at the molecular level and represent potential targets for gene-specific therapies. Modern chip techniques allow the parallel analysis of virtually all known human genes and proteins in a single experiment. Using modern high-throughput techniques, numerous potential new biomarkers for the diagnosis and prediction of prostate cancer have been identified. However, so far none of these markers has improved clinical practice. One of the most important challenges in the coming years is the extensive clinical validation of molecular data using clinically relevant end points. For this venture the pivotal prerequisite is the availability of large, comprehensively annotated and standardized high-quality bioresources.
AB - Significant cellular alterations required for the development and progression of cancers are detectable at the molecular level and represent potential targets for gene-specific therapies. Modern chip techniques allow the parallel analysis of virtually all known human genes and proteins in a single experiment. Using modern high-throughput techniques, numerous potential new biomarkers for the diagnosis and prediction of prostate cancer have been identified. However, so far none of these markers has improved clinical practice. One of the most important challenges in the coming years is the extensive clinical validation of molecular data using clinically relevant end points. For this venture the pivotal prerequisite is the availability of large, comprehensively annotated and standardized high-quality bioresources.
M3 - SCORING: Zeitschriftenaufsatz
VL - 30
SP - 111
EP - 116
JO - PATHOLOGE
JF - PATHOLOGE
SN - 0172-8113
IS - 2
M1 - 2
ER -
